JP Morgan Chase’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.19M | Buy |
1,438,434
+3,787
| +0.3% | +$8.32K | ﹤0.01% | 3839 |
|
|
2026
Q1 | $3.18M | Buy |
1,434,647
+455,535
| +47% | +$913K | ﹤0.01% | 3725 |
|
|
2025
Q4 | $1.34M | Buy |
979,112
+70,387
| +8% | +$92.8K | ﹤0.01% | 4402 |
|
|
2025
Q3 | $1.13M | Sell |
908,725
-25,298
| -3% | -$30.2K | ﹤0.01% | 4497 |
|
|
2025
Q2 | $1.06M | Sell |
934,023
-4,202,774
| -82% | -$5.58M | ﹤0.01% | 4335 |
|
|
2025
Q1 | $7.5M | Buy |
5,136,797
+1,400,665
| +37% | +$2.64M | ﹤0.01% | 2801 |
|
|
2024
Q4 | $7.96M | Sell |
3,736,132
-351,374
| -9% | -$867K | ﹤0.01% | 2920 |
|
|
2024
Q3 | $11.4M | Sell |
4,087,506
-37,348
| -0.9% | -$99.6K | ﹤0.01% | 2489 |
|
|
2024
Q2 | $9.61M | Sell |
4,124,854
-1,057,125
| -20% | -$3.12M | ﹤0.01% | 2496 |
|
|
2024
Q1 | $23.2M | Sell |
5,181,979
-1,724,782
| -25% | -$7.2M | ﹤0.01% | 1778 |
|
|
2023
Q4 | $22.2M | Sell |
6,906,761
-4,121
| -0.1% | -$11.7K | ﹤0.01% | 1767 |
|
|
2023
Q3 | $21.9M | Buy |
6,910,882
+776,487
| +13% | +$3.4M | ﹤0.01% | 1609 |
|
|
2023
Q2 | $30.5M | Buy |
6,134,395
+1,109,851
| +22% | +$6M | ﹤0.01% | 1393 |
|
|
2023
Q1 | $24.8M | Buy |
5,024,544
+1,254,261
| +33% | +$8.04M | ﹤0.01% | 1509 |
|
|
2022
Q4 | $23.7M | Sell |
3,770,283
-195,337
| -5% | -$1.81M | ﹤0.01% | 1536 |
|
|
2022
Q3 | $42.8M | Sell |
3,965,620
-537,374
| -12% | -$7.3M | 0.01% | 1122 |
|
|
2022
Q2 | $51.3M | Buy |
4,502,994
+945,877
| +27% | +$8.4M | 0.01% | 1022 |
|
|
2022
Q1 | $32.4M | Sell |
3,557,117
-66,162
| -2% | -$689K | ﹤0.01% | 1415 |
|
|
2021
Q4 | $54.1M | Buy |
3,623,279
+301,479
| +9% | +$5.32M | 0.01% | 1171 |
|
|
2021
Q3 | $85.4M | Buy |
3,321,800
+837,065
| +34% | +$19.9M | 0.01% | 937 |
|
|
2021
Q2 | $64.8M | Buy |
2,484,735
+102,868
| +4% | +$2.93M | 0.01% | 1096 |
|
|
2021
Q1 | $84.1M | Buy |
2,381,867
+424,778
| +22% | +$14.3M | 0.01% | 926 |
|
|
2020
Q4 | $49.4M | Buy |
1,957,089
+269,173
| +16% | +$8.77M | 0.01% | 1079 |
|
|
2020
Q3 | $63.7M | Buy |
1,687,916
+277,470
| +20% | +$10.5M | 0.01% | 864 |
|
|
2020
Q2 | $60.4M | Buy |
1,410,446
+1,022,462
| +264% | +$37M | 0.01% | 821 |
|
|
2020
Q1 | $7.54M | Buy |
387,984
+303,747
| +361% | +$7.24M | ﹤0.01% | 1950 |
|
|
2019
Q4 | $2.19M | Buy |
84,237
+71,479
| +560% | +$1.97M | ﹤0.01% | 3323 |
|
|
2019
Q3 | $348K | Buy |
12,758
+2,063
| +19% | +$58.8K | ﹤0.01% | 4348 |
|
|
2019
Q2 | $285K | Buy |
10,695
+5,303
| +98% | +$148K | ﹤0.01% | 4503 |
|
|
2019
Q1 | $156K | Sell |
5,392
-112
| -2% | -$3.25K | ﹤0.01% | 4726 |
|
|
2018
Q4 | $148K | Buy |
+5,504
| New | +$146K | ﹤0.01% | 4697 |
|
Other funds holding ALLO
P
FLSM
TGA
SCM
JP Morgan Chase's ALLO Position: Q2 2026 in Review
JP Morgan Chase increased its Allogene Therapeutics (ALLO) stake by 0.26% in Q2 2026, buying an estimated $8.32K and bringing the position to 1,438,434 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3839.
JP Morgan Chase first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $85.4M in Q3 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.
- JP Morgan Chase held 1,438,434 shares of Allogene Therapeutics worth $3.19M as of Q2 2026.
- JP Morgan Chase bought 3,787 Allogene Therapeutics shares in Q2 2026, an estimated $8.32K.
- Allogene Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3839 holding.
- JP Morgan Chase first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
- JP Morgan Chase's Allogene Therapeutics position peaked at $85.4M in Q3 2021.
- 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.